amniopatch

The amniopatch is an experimental therapeutic procedure developed by Cairo University for the treatment of preterm premature rupture of membranes (PPROM). The intervention involves the intraamniotic infusion of autologous maternal blood components—specifically a platelet concentrate followed by fresh frozen plasma (FFP)—administered under ultrasound guidance. The biological mechanism relies on the interaction between the infused platelets and the clotting factors within the FFP to create a fibrin-rich blood clot or 'patch' at the site of the membrane rupture. This seal is intended to restore amniotic fluid levels (preventing oligohydramnios) and prolong the pregnancy, thereby reducing the risks associated with extreme prematurity. A randomized controlled trial (NCT03473210) conducted by Cairo University evaluated this procedure in women with spontaneous PPROM between 24 and 34 weeks of gestation.

Other names

platelet concentrate + fresh frozen plasmaautologous amniopatchintraamniotic infusion of autologous blood products